NCT01447732 - Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Solid TumourAdenocarcinoma of the ColorectalAdenocarcinoma of the Pancreas

Interventions

DRUG

CEP-37250/KHK2804

"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."